Natalizumab


Study Exclusion reasons Rmk Reference
Friend, 2016 inadequate or absent control group

Friend BMC Neurol 2016; 16:150 10.1186/s12883-016-0674-4

Holmen, 2011 inadequate or absent control group 'Natalizumab was discontinued in 149 patients (12.9%) for the following reasons: a wish to become pregnant (41 patients; 27.5%)'. 'Miscarriage were reported'

Holmen Mult. Scler. 2011; 17:708-19 10.1177/1352458510394701

Kleerekooper, 2018 inadequate or absent control group

Kleerekooper Neurol Neuroimmunol Neuroinflamm 2018; 5:e424 10.1212/NXI.0000000000000424

Schneider, 2013 case report or case series

Schneider Acta Neurol. Scand. 2013; 127:e1-4 10.1111/ane.12004

Illoh, 2018 other reason

Illoh Pharmacoepidemiol Drug Saf 2018; 27:604-611 10.1002/pds.4409

Alroughani, 2019 not about fetal exposure

Alroughani Mult Scler Relat Disord 2019; 34:9-13 10.1016/j.msard.2019.06.007

van Pesch, 2014 not about fetal exposure

van Pesch Acta Neurol Belg 2014; 114:167-78 10.1007/s13760-014-0308-9

Saraste, 2018 not about fetal exposure

Saraste Mult Scler Relat Disord 2018; 21:11-18 10.1016/j.msard.2018.02.008

Vukusic, 2015 not about fetal exposure

Vukusic Mult. Scler. 2015; 21:953-5 10.1177/1352458514554056

Portaccio, 2018 not relevant outcome

Portaccio Neurology 2018; 90:e832-e839 10.1212/WNL.0000000000005068

Hellwig, 2011 same data already obtained by other studies

Hellwig Mult. Scler. 2011; 17:958-63 10.1177/1352458511401944

Beaulieu, 2018 Studies without separate analysis of the considered drug/class from other drugs/class EXCLUDED: Analyses performed for the group of pregnancies exposed to biologic exposed patients, without analysis for each substance : 27 were on infliximab, 7 on adalimumab, 3 on certolizumab, 2 each on natalizumab and ustekinumab, and 1 on vedolizumab.

Beaulieu DB Clin Gastroenterol Hepatol 2018;16:99-105 10.1016/j.cgh.2017.08.041

Bsteh, 2018 Studies without separate analysis of the considered drug/class from other drugs/class

Bsteh Mult. Scler. 2018; :1352458518816614 10.1177/1352458518816614

Alroughani, 2018 Studies without separate analysis of the considered drug/class from other drugs/class

Alroughani Neurology 2018; 90:e840-e846 10.1212/WNL.0000000000005065

Hellwig, 2010 Studies without separate analysis of the considered drug/class from other drugs/class

Hellwig J. Neurol. 2010; 257:580-3 10.1007/s00415-009-5376-z